 Home > Medical News > Medicines Company News > Jacobio will present the results of the preclinical study of the combination of KRAS G12C inhibitor and SHP2 inhibitor at the ESMO ASIA 2022 meeting

Jacobio will present the results of the preclinical study of the combination of KRAS G12C inhibitor and SHP2 inhibitor at the ESMO ASIA 2022 meeting

 Last Update: 2023-01-01
 Source: Internet
 Author: User

Tags

1 2 dimethylbenzene

drug categories

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Jacobio Pharmaceuticals (1167.
HK) will publish the results
of the KRASG12C inhibitor JAB-21822 as a single agent or in combination with the SHP2 inhibitor JAB-3312 in preclinical tumor models during the 2022 European Society of Medical Oncology Asia Conference (ESMO ASIA) from 2 December to 4 December 2022.

The results of preclinical studies showed that JAB-21822 and JAB-3312 in combination can synergistically inhibit tumor growth in a variety of KRAS G12C inhibitor-resistant tumor models, indicating that the combination of JAB-21822 and JAB-3312 is expected to overcome the adaptive resistance of tumor patients to KRAS G12C inhibitors
.
Jacobio is currently conducting clinical trials of JAB-21822 in combination with JAB-3312 (clinical trial registration number: NCT05288205).

About the summary:

Topic: Treatment options in R&D

: A study of the KRAS G12C inhibitor JAB-21822 as a single agent or in combination with the SHP2 inhibitor JAB-3312 in preclinical tumor models

Abstract number: 30P

Date: December 3, 2022

For more information, please visit the ESMO ASIA conference website:

About JAB-21822

JAB-21822 is an oral small molecule KRAS G12C inhibitor
independently developed by Jacobio.
Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors with KRASG12C mutation, including pivotal clinical trials in China for non-small cell lung cancer, monotherapy for the first-line treatment of STK11 co-mutated non-small cell lung cancer, and combination therapy with SHP2 inhibitor JAB-3312, anti-PD-1 monoclonal antibody and cetuximab
.

About JAB-3312

JAB-3312 is a highly selective SHP2 inhibitor, and Jacobio is currently conducting clinical trials of JAB-3312 in China and the United States, and has received orphan drug designation
from the Food and Drug Administration (FDA) in the United States for esophageal cancer, including esophageal squamous cell carcinoma.
Jacobio signed a global strategic collaboration agreement with AbbVie on June 1, 2020 to develop and commercialize SHP2 inhibitors
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.